FIRST WARNING WEATHER: Frost Advisory In Effect Until 9 a.m. Weather App | Current Conditions

Local

Md. Company To Study Cancer Medicine Feasibility

View Comments
Oral Medicine Syringes

CBS Baltimore (con't)

Affordable Care Act Updates:
CBSBaltimore.com/ACA

Health News & Information:
CBSBaltimore.com/Health

ROCKVILLE, Md. (AP) — A Rockville company will study the feasibility of a new cancer medicine with the large pharmaceutical company AstraZeneca.

CytImmune Sciences Inc. and AstraZeneca made the announcement on Thursday.

The two companies will work together to see whether they can transmit cancer drugs on extremely small gold particles.

CytImmune works in developing nanomedicine, which uses tiny particles of gold to carry cancer therapies directly to the site of the disease. The company says gold nanoparticles have been used safely since the 1930s to treat patients with rheumatoid arthritis.

Dr. Lawrence Tamarkin, CytImmune’s CEO, says the partnership aims to combine CytImmune’s nanotechnology research with AstraZeneca’s oncology compound to create a cancer therapy that may be widely applicable to solid tumors.

(Copyright 2012 by The Associated Press. All Rights Reserved.)

View Comments
blog comments powered by Disqus
Follow

Get every new post delivered to your Inbox.

Join 3,248 other followers